PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales: Vitolo, U., Nowakowski, G. S., Burke, J. M., Fox, C. P., Trneny, M., Chiappella, A., Waldron-Lynch, M., Hadar, N., Pachori, A., Lenz, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428988/
http://dx.doi.org/10.1097/01.HS9.0000851284.83380.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428988/
http://dx.doi.org/10.1097/01.HS9.0000851284.83380.89

Ejemplares similares